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Background. To describe the clinical characteristics of the patients who suﬀered from relapse after conventional irradiation for
nasopharyngeal carcinoma (NPC). Methods. Three hundred and ﬁfty-one consecutive patients with ﬁrst-time recurrent NPC
between January 1999 and July 2005 were included. The patients’ clinical data were reviewed, including recurrent interval time,
symptoms, signs, imaging characteristics, pathologic features, and restaging. Results. The median interval of relapse was 26.0
months.Themostcommonsymptomsinsymptomaticpatientswerenasalbloodydischarge(37.9%)andheadache(31.1%).Local
recurrence alone accounted for 73.5%. Most patients were restaged as stage III (23.1%) and stage IV (51.1%). Subgroup analysis
suggested a signiﬁcantly higher proportion of the long-latent relapses originated from early primary. A series of postreirradiation
complications were more frequent in patients with longer latency at reception. Conclusions. Most recurrent nasopharyngeal
carcinoma is advanced disease. Patients with diﬀerent recurrent interval time show diﬀerent nature behavior.
1.Introduction
Nasopharyngeal carcinoma (NPC) is a common malignancy
in Southern China. It poses a great challenge to radia-
tion oncologists worldwide, because of its propensity for
extensive local spread and its proximity to critical neural
structures. Treatment results for nasopharyngeal carcinoma
have improved in the past two decades. The improved
treatment outcome has been attributed to earlier detection
and institution of treatment, improved staging accuracy with
the application of MRI, improved treatment planning with
CT, improved dose distribution with intensity-modulated
radiation therapy, and the use of chemotherapy though local
failure is still a major hindrance to successful treatment.
The 5-year cumulative rate of nasopharynx and cervical
lymph node recurrence is between 12.0% and 22.0% [1–
5]. Domestic and foreign studies have indicated that the
clinical features of recurrent NPC may be diﬀerent from
primary NPC. Therefore, improving the recognition of the
clinical features of recurrent NPC is of great signiﬁcance to
improving early diagnosis, early treatment, and the long-
term survival rate for patients with recurrent NPC. This
study summarized and retrospectively analyzed the relevant
information of a large sample of patients with ﬁrst-time
recurrent NPC.
2.MaterialsandMethods
2.1. Patients. A retrospective review was conducted on case
records of ﬁrst-time recurrent NPC patients treated at the
Cancer Center of Sun Yat-Sen University between January
1999 and July 2005. Patients who had complete response
but developed recurrence at the primary site more than
4 months following completion of radical radiotherapy
with or without chemotherapy were identiﬁed as having
a recurrence. Most patients had undergone primary RT
usingatwo-dimensionaltechniquewithtwolateralopposing
faciocervical ﬁelds in the ﬁrst treatment phase, followed
by two lateral opposing ﬁelds in the second phase to
cover the nasopharynx, matched with a single anterior
cervical ﬁeld to cover the neck. The dose delivered to the
nasopharynx was 66–70Gy. Neoadjuvant, concurrent, or
adjuvant chemotherapy, mostly cisplatin based, was given to
89 patients (25.4%) with advanced disease.2 The Scientiﬁc World Journal
Patients were seen in followup 1 month postradiation
and then every 3 months from 3 months through 3
years, and every 1 year thereafter. During every followup
visit, disease status and treatment toxicity were assessed.
Complete physical and ﬁberoptic nasopharyngoscopy or
indirect nasopharyngeal speculum examinations were per-
formed.Biochemistryproﬁles,chestradiography,abdominal
ultrasonography, and contrast-enhanced CT or MRI of the
nasopharynx and cervical region were routine elements of
the assessment. Further investigations were arranged as in-
dicated.
Total 351 patients were included. The majority were
conﬁrmed by biopsy, and all of them showed histological
features similar to the primary tumor. Only those with
recurrence at inaccessible sites such as the skull base, the
cavernous sinus, and the intracranial area were diagnosed by
radiological features. The criteria for diagnosis of recurrence
without biopsy proof were based on progression of clinical
symptoms and/or signs that are compatible of new image
ﬁndings. Primary tumors were staged according to the 1992
Fuzhou staging system [6] as they were diagnosed, a system
approved and recommended by the Chinese Association of
Radiation Oncology in Fuzhou and widely used in mainland
China since 1992. By the end of the 20th century, the UICC
(International Union Against Cancer) and AJCC (American
Joint Committee on Cancer) staging system had been well
accepted in the high-incidence area. Therefore, the recurrent
diseases were staged both according to the 1992 Fuzhou
staging system and the 6th edition of the UICC and AJCC
staging system [7]. A comparison between these two staging
systems is summarized in Table 1.
For further study, the patients were divided into two
groups according to the latent interval from commencement
of primary treatment. Those who relapsed within 24 months
were classiﬁed as group A, >24 months as group B. This
breakpoint was chosen because (1) it was “landmark” most
commonly used in reporting; (2) it was close to the median
recurrence time (26 months) of this study; (3) it gave
reasonable sample size in each group (169 patients in group
A while 182 patients in group B).
2.2. Statistical Analysis. A l la n a l y s e sw e r ep e r f o r m e di nS P S S
16.0 for Windows. Variance analysis was used for processing
the enumerated data, a χ2 test was used for measurement
of data, and a rank-sum test was used for ranked data. All
statistical tests were two sided, and a P value of <0.05 was
considered to indicate statistical signiﬁcance.
3. Results
A total of 276 men (78.6%) and 75 women (21.4%) were
included, with the male to female ratio of about 3.7 to 1.
Patients’ age ranged from 21.0 years to 73.0 years, with a
median age of 46.0 years.
Of the 351 patients, 77.5% (272/351) were diagnosed on
pathology as having recurrence: 0.7% (2/272) had World
Health Organization (WHO) I (squamous cell carcinoma),
7.0% (19/272) had WHO II (nonkeratinizing carcinoma),
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Figure 1: The relationship between latency and cases diagnosed as
rNPC.
and 92.3% (251/272) had WHO III (undiﬀerentiated carci-
noma). Some patients with only intracranial and skull base
r ecurr enc ewhower eunablet oha v eabiopsyperformedwer e
diagnosed by MRI, CT, and positron emission tomography
(PET)-CT, at 12.3% (43/351), 8.0% (28/351), and 2.3%
(8/351), respectively.
3.1. Recurrent Interval Time. The duration from the end of
the primary treatment to the diagnosis of ﬁrst recurrence
ranged from 4.0 months to 291.0 months, with a median
recurrent interval time of 26.0 months, in which recurrent
interval time less than or equal to 6 months accounted for
6.0% (21/351), 7 months to 12 months accounted for 17.4%
(61/351), 13 months to 18 months accounted for 11.4%
(40/351), and 19 months to 24 months accounted for 13.3%
(47/351). The 2-year cumulative recurrence cases accounted
for 48.1% (169/351). Recurrence from 25 months to 60
months accounted for 34.8% (122/351), from 61 months to
120 months accounted for 14.0% (49/351), and recurrent
interval time more than 120 months accounted for 3.1%
(11/351), as seen in Figure 1.
3.2. Clinical Presentation of Recurrence. Patients with recur-
rent disease with no obvious symptoms accounted for 10.3%
(36/351), whose recurrence was found only at periodic reex-
amination. The most common symptoms in symptomatic
patients were nasal bloody discharge [37.9% (133/351)]
and headache [31.1% (109/351)], followed by tinnitus,
neck mass, nasal obstruction, and hearing loss, which were
16.2% (57/351), 15.1% (53/351), 14.8% (52/351), and 11.7%
(41/351), respectively. Other unusual symptoms included
blurred vision, a sense that ears were plugged, facial edema,
and epiphora; such symptoms did not exceed 3%. In
addition, abducens dysfunction and facial numbness caused
bycranialnervedamagewerecommonsymptomsinpatients
with recurrent NPC, accounting for 35.6% (125/351), ofThe Scientiﬁc World Journal 3
Table 1: Staging systems for nasopharyngeal carcinoma.
The sixth edition of the AJCC staging system Fuzhou 1992 staging system of China
Tumor in nasopharynx (T) Primary tumor (T)
T1: tumor conﬁned to the nasopharynx T1: Tumor conﬁned to the nasopharynx
T2: tumor extends to soft tissues of oropharynx and/or nasal fossa
T2a: without parapharyngeal extension
T2b: with parapharyngeal extension
T2: Involvement of nasal fossa, oropharynx, soft palate
prevertebral soft tissue, and parapharyngeal space extension
before SO line∗
T3: tumor invades bony structures and/or paranasal sinuses
T3: extension over SO line, involvement of anterior or
posterior cranial nerves alone, skull base, pterygoid process
zone, and pterygopalatine fossa
T4: tumor with intracranial extension and/or involvement of
cranial nerves, infratemporal fossa, hypopharynx, orbit, or
masticator space
T4: involvement of both anterior and posterior cranial
nerves, paranasal sinus, cavernous sinus, orbit, infratemporal
fossa, and direct invasion of ﬁrst or second cervical vertebra
Regional lymph nodes (N) Regional lymph nodes (N)
N0: no regional lymph node metastasis N0: no enlarged lymph node
N1: unilateral metastasis in lymph node(s), ≤6cm in greatest
dimension, above the supraclavicular fossa N1: the diameter of upper neck lymph node <4cm, movable
N2: bilateral metastasis in lymph node(s), ≤6cm in greatest
dimension, above the supraclavicular fossa
N2: lower neck§ lymph node or the diameter between 4 and
7cm
N3: metastasis in lymph node(s)
N3a: >6cm in greatest dimension
N3b: extension to the supraclavicular fossa
N3: supraclavicular lymph node or the diameter >7cmor
ﬁxed or skin inﬁltration
Distant metastasis (M)
M0: no distant metastasis
M1: distant metastasis
Distant metastasis (M)
M0: absence of distant metastasis
M1: presence distant metastasis
Stage grouping Stage grouping
Stage I: T1 N0 M0 Stage I: T1 N0 M0
Stage IIA: T2a N0 M0 Stage II: T2 N0-1 M0
Stage IIB: T1-2 N1 M0; T2b N0 M0; T1-2 Stage III: T3 N0-2 M0; T1-3 N2 M0
N1 M0 Stage IVA: T4 any N, M0
Stage III: T1-3 N2 M0; T3 N0-1 M0 Stage IVB: any T, any N, M1
Stage IVA: T4 N0-2 M0; any T N3, M0
Stage IVB: any T N3 M0
Stage IVC: any T, any N M1
∗The line connected from the styloid process to the midpoint on posterior edge of the great occipital foramen.
§T h eb o r d e rb e t w e e nu p p e ra n dl o w e rn e c ki st h el o w e rm a r g i no ft h ec r i c o i dc a r t i l a g e .
which the most common was for the damage of the abduc-
tion nerve and trigeminal nerve branch 2, accounting for
20.2% (71/351) and 19.1% (67/351), respectively, followed
bythedamageoftrigeminalnervebranches1and3,account-
ing for 10.0% (35/351) and 9.1% (32/351), respectively. The
rate of other cranial nerve injuries was below 5%.
3.3. Patterns of Recurrence and Distant Metastasis. Recur-
rence in local alone was the most common [73.5%
(258/351)], followed by the concurrent recurrence in both
local and regional neck nodes [21.7% (76/351)]. Regional
failure alone was rare [4.8% (17/351)]. Total cumulative
rate of distant metastasis before the end of treatment for
recurrence was 6.6% (23/351), of which metastasis occurred
43.5%(10/23)inbone,21.7%(5/23)indistantlymphnodes,
13.0% (3/23) in the lungs, 4.3% (1/23) in the liver, 13.0%
(3/23) in multiorgan sites, and 4.3% (1/23) in the right
parotid gland and the right medial canthus.
3.4. Stages and Restages. For 27 patients ﬁrst treated at other
hospitals, the primary stages were unknown. 324 patients
with primary nasopharyngeal carcinoma were retrospec-
tively staged according to the 1992 Fuzhou staging system,
of which 5.2% had stage I disease, 31.5% had stage II, 46.6%
had stage III, and 16.7% had stage IVa disease.
Recurrent tumors were restaged as follows: stage I
accounted for 7.4%, stage II accounted for 12.0%, stage
III accounted for 27.4%, stage IVa accounted for 46.7%,
and stage IVb accounted for 6.6%. As restaged according to
the 6th edition of UICC and AJCC staging system, stage I
accounted for 6.8% (24/351), stage IIa accounted for 1.7%
(6/351), stage IIb accounted for 17.4% (61/351), stage III
accountedfor23.1%(81/351),stageIVaaccountedfor42.5%
(149/351), stage IVb accounted for 2.0% (7/351), and stage
IVc accounted for 6.6% (23/351). A correlation between the
stages at initial diagnosis and at recurrence was shown in
Table 2.4 The Scientiﬁc World Journal
Table 2: Stage and restage according to the 1992 Fuzhou staging system.
Initial stage
No. of patients by recurrent stage
Total
I II III IVa IVb
I 24470 1 7
II 11 15 30 40 6 102
III 8 18 46 67 12 151
IVa 3 2 7 39 3 54
Total 24 39 87 153 21 324
The primary and recurrent stages according to the 1992
Fuzhou staging criteria were compared by Wilcoxon signed
rank test. 52.5% (170/324) of patients’ recurrent T-stages
were more advanced than the primary T-stages, while 19.8%
(64/324) of primary T-stages were more advanced than
the recurrent T-stages (P<0.001). 46.7% (151/324) of
patients’ recurrent N-stages were earlier than the primary
N-stages, while 13.3% (43/324) of primary N-stages were
earlier than the recurrent N-stages (P<0.001). For the
overall TNM stages, 53.4% (173/324) of patients’ recurrent
stages were more advanced than the primary stages, while
15.1% (49/324) primary stages were more advanced than the
recurrent stages (P<0.001).
3.5.TumorInvasion. Thecommoninvasionsitesofrecurrent
NPC revealed by imaging in the whole group included the
skull base accounting for 54.4% (191/351), the prestyloid
space for 43.3% (152/351), the carotid sheath area for
31.3% (110/351), the anterior group of cranial nerves for
28.2% (99/351), the cavernous sinus for 25.6% (90/351),
the paranasal sinuses for 22.8% (80/351), the oropharynx
for 18.5% (65/351), the nasal cavity for 17.9% (63/351), the
intracranial invasion for 12.5% (44/351), the pterygomaxil-
lary fossa for 11.4% (40/351), the posterior group of cranial
nerves for 5.7% (20/351), the infratemporal fossa for 5.1%
(18/351), the orbital apex for 5.1% (18/351), the soft palate
for 3.1% (11/351), the cervical vertebrae for 2.3% (8/351),
and the hypopharynx for 0.6% (2/351). Sites of primary
and recurrent tumor invasion were compared by McNemar’s
test (Table 3). The results showed that the invasion rates of
the oropharynx, the prestyloid space, and the carotid artery
sheath by the primary tumor were signiﬁcantly higher than
those by the recurrence. Conversely, the invasion rates of
the skull base, the paranasal sinuses, the cranial nerves, the
cavernous sinus, the intracranial space, the pterygomaxillary
fossa, the infratemporal fossa, the orbital apex, and the soft
palate by recurrent tumors were signiﬁcantly higher than
those by the primary tumor.
3.6. Subgroups Compare. G r o u pAa n dg r o u pBw e r ec o m -
pared in respect of the above (Table 4) .T h em a l et of e m a l e
r a t i oi sh i g h e ri ng r o u pA( 5 . 2 6:1 ) ,w h i l eg r o u pBi s2 . 7 9:1
(P = 0.02). The median age ﬁrst diagnosed as nasophar-
yngeal carcinoma is similar in two groups (P = 0.77). A
signiﬁcantly higher proportion of the long-latent relapses
originated from early primary; the percentage of patients
with T1 and T2 primary was 40.0% in group A, while
59.2% in group B; the percentage of patients with T3 and
T4 primary was 60.0% in group A, while 40.8% in group B
(P = 0.01). However, there was no diﬀerence in primary N-
stage between two groups (P = 0.82).
The percentage of patients diagnosed as relapsed disease
by pathology was lower in group A (70.4% versus 84.1%,
P<0.01). Nasal obstruction and hearing loss had signiﬁcant
diﬀerence between two groups among the symptoms while
tumor relapsed. There were only 10.1% in group A with
chief complaint of nasal obstruction, while 19.2% in group
B( P = 0.02). Likewise, there were 6.5% in group A with
chief complaint of hearing loss, while 16.5% in group B (P<
0.01). Higher incidence of postreirradiation complications
was observed with longer latency. there were 2.4% in group
A with neck ﬁbrosis and induration, while 13.2% in group
B( P<0.01). The cumulative percentage of MRI scan
evidenced temporal lobe encephalopathy in the two groups
was 0% and 3.8%, respectively (P = 0.04). Though the
diﬀerences of recurrent T-stage, N-stage, and the proportion
of coexisting distant metastases were insigniﬁcant between
two groups, the invasion rates of some structures associated
with T4-stage were higher in group A. 9.6% in group A
had the cavernous sinus invasion, while 3.4% in group B
(P = 0.04). The percentage of intracranial invasion in the
two groups was 16.6% and 8.8%, respectively (P = 0.04).
4. Discussion
Recurrence is one of the common failures after radiotherapy
for nasopharyngeal carcinoma (NPC). A lot of reports
focussed on the salvage treatment of recurrence, but few
explored the characteristic of recurrent NPC specially. Our
study was intended to shed more light on this aspect.
In our series, patients’ median age is 46.0 years, which
is consistent with that of other studies [8, 9]. The incidence
of recurrent NPC was higher in men than in women. The
male to female ratio was about 2.5 to 1 in some reports
[8, 9], while 3.7 to 1 in ours, which is similar to the data
reported by Teo et al. [10]. The mainly pathologic type of
newly diagnosed patients in regions with high incidence
was WHO III, so as our recurrent patients. A small part of
the patients were not conﬁrmed relapse disease by biopsy.
The usual condition was the patients with tumor over deep
submucosa, basilar skull, or intracranial area adjacent to the
critical structures that might have technique diﬃculty or
high morbidity probability for biopsy.The Scientiﬁc World Journal 5
Table 3: Comparison of tumor invasion in patients with pNPC∗ and rNPC.
Tumor invasion No invasion in rNPC (case) Invasion in rNPC (case) P value
Oropharynx <0.01
No invasion in pNPC (case) 157 31
Invasion in pNPC (case) 66 20
Nasal cavity 0.81
No invasion in pNPC (case) 189 37
Invasion in pNPC (case) 34 14
Soft palate <0.01
No invasion in pNPC (case) 265 9
Invasion in pNPC (case) 0 0
Prestyloid space <0.01
No invasion in pNPC (case) 52 32
Invasion in pNPC (case) 105 85
C a r o t i ds h e a t ha r e a <0.01
No invasion in pNPC (case) 114 41
Invasion in pNPC (case) 80 39
Pterygopalatine fossa <0.01
No invasion in pNPC (case) 230 30
Invasion in pNPC (case) 10 4
Skull base <0.01
No invasion in pNPC (case) 114 102
Invasion in pNPC (case) 16 42
A n t e r i o rg r o u po fc r a n i a ln e r v e <0.01
No invasion in pNPC (case) 186 65
Invasion in pNPC (case) 10 13
Posterior group of cranial nerve <0.01
No invasion in pNPC (case) 259 13
Invasion in pNPC (case) 2 0
Paranasal sinuses <0.01
No invasion in pNPC (case) 194 54
Invasion in pNPC (case) 15 11
Infratemporal fossa <0.01
No invasion in pNPC (case) 256 15
Invasion in pNPC (case) 3 0
Orbital apex 0.03
No invasion in pNPC (case) 255 14
Invasion in pNPC (case) 4 1
Cavernous sinus <0.01
No invasion in pNPC (case) 197 60
Invasion in pNPC (case) 8 9
Cervical vertebrae 0.06
No invasion in pNPC (case) 269 5
Invasion in pNPC (case) 0 0
Intracranial <0.01
No invasion in pNPC (case) 238 33
Invasion in pNPC (case) 1 2
Laryngopharynx 0.50
No invasion in pNPC (case) 272 2
Invasion in pNPC (case) 0 0
∗Primary nasopharyngeal carcinoma (total 274 patients had clear radiographic image data).6 The Scientiﬁc World Journal
Table 4: Changes in clinical features with increasing latency.
Features Group A (2y) GroupB(2y) P value
Sex 0.02
Male 142 134
Female 27 48
Age 43.0 42.5 0.77
T-stage∗ 0.01
T1 9 30
T2 53 70
T3 62 51
T4 31 18
N-stage∗ 0.82
Diagnosis <0.01
Pathology 119 153
CT 16 12
MRI 31 12
PET-CT 3 5
rT-stage∗ 0.43
rT0 10 7
rT1 14 18
rT2 18 24
rT3 42 56
rT4 85 77
rN-stage∗ 0.38
rM-stage∗ 0.52
∗Staged by the 1992 Fuzhou staging system (total 324 patients had clear
pretreatment stages).
Similartothoseofotherreports[11,12]withthemedian
recurrent interval time of about two years, our data is 26.0
months. The frequency of recurrent cases reached its peak
at 6 ∼ 12 months after the end of the primary treatment
then decreased gradually. Patients relapsed within 2 years
accounted for nearly half of the total, which were considered
at high risk for recurrence. Cases relapsed between 2 years
and 5 years decreased by nearly one-third compared to those
within 2 years, in which we should maintain sharp vigilance
to the danger of recurrence. Those who relapsed between 5
yearsand10yearsaccountedforonly14.0%,whichindicated
a low-risk period. Only very few patients were seen with
relapse after 10 years (3.1%), which belonged to the stable
period of cured NPC.
The painless enlargement of the upper cervical lymph
node(s) was the most common presenting feature in about
40% to 75.8% of primary nasopharyngeal carcinoma [2,
3, 13], followed by nasal symptoms and aural problems.
However, in this group, because isolated local failure relapse
accounted for the majority of the recurrent patterns, neck
mass was only found in 14.8% of chief complaints.s It should
be noted that the incidence of headache is signiﬁcantly high
inourseries,whichwasnotmentionedinotherreports[2,3]
of primary nasopharyngeal carcinoma expect for the study
from HK [13]. This could be attributable to several factors:
(1) the vast majority of recurrent patients were at late stages
of disease, common with destruction at the base of the skull
and/or intracranial invasion; (2) some patients had radiation
encephalopathyafterprimaryradiotherapy;(3)theradiation
ulceration/necrosis complicated with infection made the
situation worse. The incidence of cranial nerve injury in
our series (35.3%) appears much higher than that in newly
diagnosed patients (11.7% to 20.0%) [2, 3, 13]. The most
frequently involved nerves were V, followed by VI, which
is in accordance with a previous study [2]. Radiotherapy-
related cranial nerve palsy may occur in patients with NPC
after they receive conventional radiotherapy. But hypoglossal
nerve palsy was found most frequently, followed by vagus
nerve palsy and recurrent laryngeal nerve palsy [5, 14]. So
thehighincidenceofcranialnerveinjuryinourseriesmaybe
due to the extensive invasion of the recurrent disease, other
than radiotherapy-related cranial nerve palsy.
Our data indicated that isolate local relapse is the most
common recurrence pattern, which compares favorably with
the results published in several contemporary series [5, 12,
15]. As to our knowledge, retreatment of locally recurrent
NPC is associated with a high risk of complications [9].
What’s more, patients with locoregional failure have an
increased risk of distant metastasis [16]. Given the poor out-
come and highly associated complications with retreatment,
raising the local control rate is of great importance.
In our patients, about 60% had advanced stages (stage
III–IV) at initial diagnosis. By the time relapsed, the percent-
age had risen to over 80%. There have been a few studies
which reported a detailed analysis of stages and restages of
patients with recurrent nasopharyngeal carcinoma. Leung et
al. [5] reported that of the patients with local recurrence
who had early T classiﬁcation at diagnosis, 70% had early
T classiﬁcation (rT1-2) at recurrence; of the patients with
localrecurrencewhohadadvancedTclassiﬁcation(rT3-4)at
diagnosis, 75% had advanced T classiﬁcation at recurrence.
Yu et al. [15] found that 50% of all local failures were
advanced (rT3 and rT4). The recurrent T classiﬁcation was
the same as the initial T classiﬁcation in 82% of the patients.
But in the majority of our patients, recurrent T-stages were
more advanced than the primary T-stages, while recurrent
N-stages were earlier than the primary N-stages. For the
overall TNM stages, more than half of the patients’ recurrent
stages were more advanced than the primary stages. All
diﬀerences were statistically signiﬁcant. Carefully analyzing
the three studies, we found that the percentages of advanced
stages at initial diagnosis in the other two series were much
smaller than ours, which may be one of the reasons behind
the susceptibility of the diﬀerent results of stage and restage
comparisons.
By comparing the invasion sites between primary and
recurrent tumors, structures adjacent to the nasopharynx,
such as the oropharynx, the prestyloid space, and the carotid
artery sheath, the probability of invasion can be observed
to be signiﬁcantly lower in recurrent NPC. Conversely,
regarding the structures far from the nasopharynx, such as
the skull base, the paranasal sinuses, the cranial nerves, the
cavernous sinus, the intracranial cavity, the pterygomaxillary
fossa, the infratemporal fossa, the orbital apex, and the soft
palate, the probability of invasion is signiﬁcantly higher inThe Scientiﬁc World Journal 7
recurrent disease than in primary disease. Areas neighboring
the nasopharynx were in the high-dose area during the ﬁrst
treatment, while the areas far away from the nasopharynx
received low or no dose exposure. So we speculate the
possible explanation for this phenomena. The tumor cells of
subclinical lesions in low-dose areas receive mostly sublethal
damage and can be repaired, survive, continue to split,
and lead to tumor recurrence? Another explanation is
that the patients carry genes susceptible to NPC and had
a tendency of recurrence under external factors, but the
normal structure of the areas adjacent to the nasopharynx
was destroyed by high-intensity rays at the ﬁrst treatment,
with the local blood supply reduced and unfavorable for
tumor growth, so the tumor relocates and occurs far away
from the nasopharynx. Furthermore, Nicholls et al. [17]
suggested that at least a proportion of relapses were new
growths rather than genuine recurrences, as 14% of cases
showed extensive in situ changes. In such circumstance, it
should come as no shock that the new tumor would arise
from the area a little far away from the nasopharynx, where
the blood supply is abundant.
The latency for nasopharyngeal carcinoma recurrence
varies widely. For exploring if there is some diﬀerence in
the clinical manifestation between recurrence with short
latency and long latency, we made detailed analysis and
comparisonbetweenthetwogroups(2yearsand>2years).
A lot of large studies [2, 18] showed a worse prognosis
for male with nasopharyngeal carcinoma. In our series, the
male to female ratio is signiﬁcantly higher in group A. Lee
et al. [11] reported that the prognosis of nasopharyngeal
recurrence with long latency was signiﬁcantly better. So the
male tendency to relapse earlier should account for one of
the explanations why they have worse prognosis. As most
of the long survivors were patients with limited disease at
presentation, it is not surprising that a higher proportion
of long-latent relapse occurred in patients with early T-
stages at the initial diagnosis. The percentage of patients
diagnosed as relapsed disease by pathology was signiﬁcantly
lower in group A. Marx [19] reported that irradiation may
cause hypoxia, hypovascularity, and hypocellularity and may
impair normal collagen synthesis and cell production, which
may lead to tissue breakdown. Then the lesion will be
repaired by the proliferation of ﬁbroblasts. Therefore, the
pathological ﬁndings in a short time after irradiation are
mainly necrotic tissue and ﬁbrous tissue, which induce the
rate of diagnosis by pathology to be lower in patients with
short recurrence interval time.
Chen et al. [20] found that it was easy to lead to nasal
synechia(theincidenceratewasabout25.2%) whenthedose
of external irradiation is high or adding intracavitary irradi-
ation or using the decongestant for long time. Ho et al. [21]
reported that sensorineural hearing loss started early after
irradiation in the patients with nasopharyngeal carcinoma.
The acute adverse eﬀect on bone conduction threshold
recovered in 40% of ears at 2 years after irradiation. On long-
term followup, the probability of sensorineural threshold
deterioration increased. In other words, nasal synechia and
hearing loss were common complications in patients after
irradiation and became worse over time. Sometimes, it
is diﬃcult to distinguish whether they are complications
or new symptoms. So nasal obstruction and hearing loss
were seen more often in group B as recurrent symptoms.
Likewise, there is no doubt that a series of postreirradiation
c o m p l i c a t i o n ss u c ha sn e c kﬁ b r o s i sa n dt e m p o r a ll o b e
encephalopathy were more frequent in patients with longer
latency.
The diﬀerences of recurrent T-stage, N-stage, and the
proportion of coexisting distant metastases were insigniﬁ-
cant between two groups in our study, which conﬂicted with
Lee’s observation [11]. Lee et al. found that a signiﬁcantly
lower proportion of the long-latent relapse had tumors still
conﬁned within the nasopharynx (rT1) at detection of recur-
rence. As rT-stage was one of the most important prognostic
factors, and the proportion of patients reirradiated was
similar, they could not explain well why recurrence with long
latency was associated with better prognosis. This problem
will need to be further gone into. Perhaps we can expect a
breakthrough at gene and protein level.
The current study describes the clinical characteristics
of recurrent nasopharyngeal carcinoma. Patients relapsed
within 2 years accounted for nearly half of the total. Isolated
local relapse is the major recurrent pattern. Most patients
had advanced disease at initial diagnosis, and the rate was
even higher while recurrence. Subgroup analysis suggested
that the male tents to relapse earlier. A higher proportion of
long-latent relapse occurred in patients with early T-stages at
initial diagnosis. A series of postreirradiation complications
were more frequent in patients with longer latency at
reception.Moreresearchisneededtoimprovetheknowledge
of recurrent nasopharyngeal carcinoma in hope to work out
the prevention or radical cure of the disease.
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